Bank Julius Baer & Co. Ltd Zurich Has $34.83 Million Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Bank Julius Baer & Co. Ltd Zurich raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 429,936 shares of the biopharmaceutical company’s stock after buying an additional 12,617 shares during the period. Bank Julius Baer & Co. Ltd Zurich’s holdings in Gilead Sciences were worth $34,829,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Strategic Blueprint LLC boosted its position in shares of Gilead Sciences by 8.1% in the 3rd quarter. Strategic Blueprint LLC now owns 4,388 shares of the biopharmaceutical company’s stock worth $329,000 after purchasing an additional 328 shares during the last quarter. Proficio Capital Partners LLC bought a new position in shares of Gilead Sciences in the 3rd quarter worth $207,000. Koshinski Asset Management Inc. boosted its position in shares of Gilead Sciences by 5.1% in the 3rd quarter. Koshinski Asset Management Inc. now owns 2,975 shares of the biopharmaceutical company’s stock worth $223,000 after purchasing an additional 145 shares during the last quarter. Harrington Investments INC lifted its holdings in Gilead Sciences by 2.2% during the third quarter. Harrington Investments INC now owns 20,786 shares of the biopharmaceutical company’s stock worth $1,558,000 after acquiring an additional 450 shares in the last quarter. Finally, Verity & Verity LLC lifted its holdings in Gilead Sciences by 0.8% during the third quarter. Verity & Verity LLC now owns 333,109 shares of the biopharmaceutical company’s stock worth $26,539,000 after acquiring an additional 2,708 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

GILD has been the topic of several recent analyst reports. Oppenheimer reiterated an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a report on Friday, April 19th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Friday. Morgan Stanley lowered their target price on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research report on Friday. TD Cowen lowered their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Friday. Finally, HSBC raised Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price on the stock in a research report on Wednesday. Eleven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of “Hold” and a consensus price target of $83.87.

Gilead Sciences Price Performance

Shares of GILD stock traded up $0.15 during trading on Friday, hitting $65.42. The company had a trading volume of 12,349,126 shares, compared to its average volume of 7,477,028. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The firm has a market capitalization of $81.45 billion, a P/E ratio of 14.53, a price-to-earnings-growth ratio of 1.20 and a beta of 0.19. The stock’s 50-day moving average price is $71.40 and its 200 day moving average price is $76.32. Gilead Sciences, Inc. has a one year low of $64.63 and a one year high of $87.86.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. During the same period in the previous year, the company posted $1.37 earnings per share. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. Equities analysts expect that Gilead Sciences, Inc. will post 4.2 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were given a dividend of $0.77 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a yield of 4.71%. The ex-dividend date of this dividend was Thursday, March 14th. Gilead Sciences’s payout ratio is currently 68.44%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.